Article
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2021
Griesinger Frank, Eberhardt Wilfried, Nusch Arnd, Reiser Marcel, Zahn Mark-Oliver, Maintz Christoph, Bernhardt Christiane, Losem Christoph, Stenzinger Albrecht, Heukamp Lukas C, Büttner Reinhard, Marschner Norbert, Jänicke Martina, Fleitz Annette, Spring Lisa, Sahlmann Jörg, Karatas Aysun, Hipper Annette, Weichert Wilko, Heilmann Monika, Sadjadian Parvis, Gleiber Wolfgang, Grah Christian, Waller Cornelius F, Reck Martin, Rittmeyer Achim, Christopoulos Petros, Sebastian Martin, Thomas Michael
Abstract excerpt
OBJECTIVES: An increasing number of treatment-determining biomarkers has been identified in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation of these recommendations in the "real-world" setting are scarce. This study presents comprehensive details on the frequency, methodology and results of biomarker testing of...
Topics
Join the communities discussing this publication.